Company Description: Life Bio is a clinical-stage [SR3.1]biotechnology company pioneering cellular rejuvenation therapies to reverse and prevent multiple diseases of aging. The company’s proprietary Partial Epigenetic Reprogramming (PER) platform utilizes three transcription factors—Oct4, Sox2, and Klf4—to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, thereby offering the potential to address a wide range of serious age-related diseases. Life Bio’s lead program, ER-100, is being developed for optic neuropathies, including glaucoma and non-arteritic anterior ischemic optic neuropathy (NAION), with Phase 1 initiated in the first quarter of 2026 for both indications. Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential

Goal for Presentation: Create awareness and interest among investors in Life Bio. Additionally, to educate the audience on the emerging and exciting field of cellular rejuvenation therapies, utilizing partial epigenetic reprogramming to reverse and prevent diseases associated with aging.

Additional Comments: The company has just completed a private financing and has cash through 3Q27.

Who referred you to this application?: Bakers at Stifel and Leerink recommended the conference, as well as multiple biotech investors, given our stage and technology